PerkinElmer
check quantity

PD-1 (human) LANCE Ultra TR-FRET Detection Kit, 10,000 Assay Points

The LANCE® Ultra Human PD-1 Detection Kit is designed for detection and quantitation of human PD-1 in buffered solution and cell culture media using a homogeneous TR-FRET (no-wash steps, no separation steps) assay.

For research use only. Not for use in diagnostic procedures.

Part Number
Unit Size
List Price
Your Price
Quantity
TRF1343C
500 Assay Points
806.00 USD
 
more
TRF1343M
10,000 Assay Points
10700.00 USD
 
more
Buy Now

Please enter valid quantity

Please log in to add favorites.

NULL OR EMPTY CART

Overview

The LANCE® Ultra Human PD-1 Detection Kit is designed for detection and quantitation of human PD-1 in buffered solution and cell culture media using a homogeneous TR-FRET (no-wash steps, no separation steps) assay.

  • No-wash steps, no separation steps
  • TR-FRET technology
  • Sensitive detection
  • High reproducibility
  • Faster time-to-results
  • Easy automation
  • 96-well, 384-well, and 1536-well formats

 

 

LANCE® and LANCE® (Lanthanide chelate excite) Ultra are our TR-FRET (time-resolved fluorescence resonance energy transfer), homogeneous (no wash) technologies. One antibody of interest is labeled with a donor fluorophore (a LANCE Europium chelate) and the second molecule is labeled with an acceptor fluorophore (ULight™ dye). Upon excitation at 320 or 340 nm, energy can be transferred from the donor Europium chelate to the acceptor fluorophore if sufficiently close for FRET (~10 nm). This results in the emission of light at 665 nm.

 

Programmed cell death protein 1 (PD-1), also known as cluster of differentiation 279 (CD279), belongs to immunoglobulin superfamily and is a transmembrane receptor protein. PD-1 is present on T –cells or B-cells and binds to ligands, such as PD-L1 and PD-L2, to down regulate the immune system by modulating many other cytokines and cytokine receptors. Anti PD-1 antibody drugs been shown to enhance the immune systems of several types of cancer patients.

Specifications

Assay Target PD-1
Assay Target Class Protein
Automation Compatible Yes
Detection Method Time-Resolved Fluorescence (TRF), TR-FRET
Experimental Type In vitro
Product Brand Name LANCE Ultra
Shipping Condition Blue Ice
Therapeutic Area Cancer
Unit Size 10,000 Assay Points
Resources, Events & More
  • All

Application Note

Measuring PD-L1 and PD-1 Expression in Human Cells with LANCE Ultra TR-FRET

Immuno-oncology is an exciting area within cancer research and among the most promising approaches to activating therapeutic antitumor immunity is through the blockade of immune checkpoints. The programmed cell death-1 (PD-1) immune checkpoint pathway is a negative regulator of T cell immune function. When PD-1 is bound to programmed cell death-ligand 1 (PD-L1), T cell response is suppressed. Many tumor cells escape anti-tumor immunity through their expression of Programmed Death Ligand 1 (PD-L1 or B7-H1), which interacts with T cell-expressed PD-1 and results in T cell apoptosis. PD-L1 expression has been studied in multiple different cancers. While several anti-PD-1 or PD-L1 monoclonal antibodies that block the PD-1/ PD-L1 complex formation have been developed to date, there remains a need for more robust, rapid, high-throughput assays to identify and qualify novel inhibitors of PD-1/PD-L1 binding and assays to detect expression levels of both binding partners. Find out how LANCE® Ultra Technology provides a fast, powerful, homogeneous platform for identifying and characterizing endogenous PD-L1 and PD-1 expression in human cells.

PDF 4 MB

Brochure